In all four trials comparing NOACs to warfarin in patients with AF, concurrent aspirin use was associated with higher incidence of major haemorrhage regardless of the treatment arm. However, the incidence of major haemorrhage when a NOAC was co-administered with aspirin was consistently lower than that seen with warfarin (dabigatran 150 mg and 110 mg vs. warfarin: 4.08% year−1 and 3.65% year−1 vs. 4.32% year−1; rivaroxaban vs. warfarin: 2.73% year−1 vs. 3.49% year−1; apixaban vs. warfarin: 2.7% year−1 vs. 3.7%; edoxaban 60 mg and 30 mg vs. warfarin: 3.62% year−1 and 2.00% year−1 vs. 4.71% year−1 [21-24, 78]). These data suggest that the NOACs offer promising safety advantages compared to warfarin when used in conjunction with antiplatelet therapy, but this must be confirmed in future studies.